Autolus Therapeutics PLC (AUTL) Stock Analysis
Verdict: WATCH (do not buy)
Autolus is a high-science CAR-T play facing a critical liquidity crunch as $310M in annual burn collides with a $104M cash pile.
Investment score: 44/100
Analysis as of
Is Autolus Therapeutics PLC stock worth reviewing? AI model thesis
The AI model views Autolus as a high-risk speculative asset where clinical promise is overshadowed by immediate financing needs.
7-factor investment score
- Valuation: 40/100 (weight 20%)
- Financial Health: 15/100 (weight 15%)
- Technical Momentum: 35/100 (weight 15%)
- Earnings Quality: 30/100 (weight 15%)
- Insider Sentiment: 50/100 (weight 10%)
- Analyst Consensus: 85/100 (weight 10%)
- Risk-Adjusted Return: 35/100 (weight 15%)
Autolus Therapeutics PLC opportunities and risks
What speaks for AUTL
- Obe-cel Regulatory Success
What speaks against AUTL
- Imminent Cash Runway Exhaustion
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| AUTL | n/a | 4.2x | n/a | -11.2% | -312.0% | -75.5% |
| CMPS | n/a | 0.0x | n/a | 0.0% | 0.0% | -14.7% |
| GNS.L | 29.7x | 2.1x | 14.2x | 100.1% | 7.1% | 4.0% |
| OXB.L | n/a | 4.1x | n/a | 39.1% | -17.9% | -1.5% |
| SLNCF | n/a | 564.9x | n/a | 66.4% | -9243.0% | -12.6% |
| AVCT.L | n/a | 2901.6x | n/a | -1031.9% | -33961.1% | -7.6% |
| Peer median | n/a | 4.1x | n/a | 39.1% | -17.9% | -7.6% |
Frequently asked questions about Autolus Therapeutics PLC (AUTL)
Is AUTL stock a good investment?
The cached TradeMates AI model rates Autolus Therapeutics PLC as WATCH (do not buy) with an investment score of 44/100. The AI model views Autolus as a high-risk speculative asset where clinical promise is overshadowed by immediate financing needs. This is algorithmic model output, not personal investment advice.
Is AUTL stock a buy?
The TradeMates model verdict for AUTL is WATCH (do not buy) with an investment score of 44/100. Treat this as a model signal to review, not a personal buy recommendation.